Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis

被引：0
作者：
Mauro Zaffaroni
Annalisa Rizzo
Silvana Maria Baldini
Angelo Ghezzi
Giancarlo Comi
机构：
[1] Centro Studi Sclerosi Multipla,
[2] S. Raffaele Hospital and University,undefined
来源：
Neurological Sciences | 2008年 / 29卷
关键词：
Interferon beta; Glatiramer acetate; Mitoxantrone; Combination therapy; Induction therapy; Rescue therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-β (IFN-β) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/ persistently active disease in spite of IFN-β (add-on/combination therapy), or for increased disability suggesting a secondary progression (rescue therapy). After almost 2-year follow-up, relapse rate and disability decreased very significantly in the two former groups while MX was essentially ineffective as rescue therapy. Induction therapy is a valid option for very aggressive/active CIS and MS at onset.
引用
收藏
页码：230 / 232
页数：2
相关论文
共 50 条
[31]   Mitoxantrone as rescue therapy in two children with worsening multiple sclerosis [J].
Heckel, Martina ;
Kieseier, Bernd C. ;
Schaper, Joerg ;
Mayatepek, Ertan ;
Rosenbaum, Thorsten .
JOURNAL OF PEDIATRIC NEUROLOGY, 2005, 3 (04) :237-242
[32]   Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy [J].
Galeazzi, GM ;
Ferrari, S ;
Giaroli, G ;
Mackinnon, A ;
Merelli, E ;
Motti, L ;
Rigatelli, M .
NEUROLOGICAL SCIENCES, 2005, 26 (04) :255-262
[33]   Predictors of long–term clinical response to interferon beta therapy in relapsing multiple sclerosis [J].
V. Tomassini ;
A. Paolillo ;
P. Russo ;
E. Giugni ;
L. Prosperini ;
C. Gasperini ;
G. Antonelli ;
St. Bastianello ;
C. Pozzilli .
Journal of Neurology, 2006, 253 :287-293
[34]   Minimal change disease with interferon-beta therapy for relapsing remitting multiple sclerosis [J].
Aravindan, Ananthakrishnapuram ;
Yong, Jim ;
Killingsworth, Murray ;
Suranyi, Michael ;
Wong, Jeffrey .
CLINICAL KIDNEY JOURNAL, 2010, 3 (02) :132-134
[35]   Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy [J].
G. M. Galeazzi ;
S. Ferrari ;
G. Giaroli ;
A. Mackinnon ;
E. Merelli ;
L. Motti ;
M. Rigatelli .
Neurological Sciences, 2005, 26 :255-262
[36]   Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients. [J].
Le Page, E ;
Leray, E ;
Taurin, G ;
Coustans, M ;
Chaperon, J ;
Edan, G .
REVUE NEUROLOGIQUE, 2006, 162 (02) :185-194
[37]   Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response [J].
Graber, Jerome J. ;
Ford, David ;
Zhan, Min ;
Francis, Gordon ;
Panitch, Hillel ;
Dhib-Jalbut, Suhayl .
JOURNAL OF NEUROIMMUNOLOGY, 2007, 185 (1-2) :168-174
[38]   Natalizumab as induction therapy in multiple sclerosis [J].
Corlobe, A. ;
Charif, M. ;
Mania, A. ;
Outteryck, O. ;
de Seze, J. ;
Labauge, P. .
REVUE NEUROLOGIQUE, 2014, 170 (01) :2-5
[39]   Prediction of response to interferon therapy in multiple sclerosis [J].
Sellebjerg, F. ;
Sondergaard, H. B. ;
Koch-Henriksen, N. ;
Sorensen, P. S. ;
Oturai, A. B. .
ACTA NEUROLOGICA SCANDINAVICA, 2014, 130 (04) :268-275
[40]   Interferon beta, birth weight and pregnancy in multiple sclerosis [J].
Kerstin Hellwig ;
Heike Agne ;
Ralf Gold .
Journal of Neurology, 2009, 256 :830-831
12345